GSK amends commercial deal with Scynexis as antifungal recall drags into 2024

When GSK laid out $90 million upfront to acquire rights to Scynexis’ antifungal Brexafemme last spring, the British pharma threw a lifeline to a company whose blockbuster launch ambitions had hit the skids. But now, as an October recall of the antifungal bleeds into 2024, the scope of GSK’s financial assistance has waned.